Necroptosis Pathway in Neurodegeneration

Migration, Crosslink

📖

Necroptosis Pathway in Neurodegeneration

active

wiki page Created: 2026-04-02T07:20:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-necroptosis-pathway-neur

📖 Wiki Page

mechanism3402 wordssynced 2026-04-02

Necroptosis Pathway in Neurodegeneration

Path: mechanisms/necroptosis-pathway-neurodegeneration Title: Necroptosis Pathway in Neurodegeneration Tags: section:mechanisms, kind:pathology, topic:cell-death, topic:necroptosis, topic:inflammation, topic:alzheimer, topic:parkinson

Overview

Necroptosis is a programmed form of necrotic cell death characterized by cellular swelling, membrane rupture, and release of intracellular contents that trigger inflammatory responses[@degterev2005]. This cell death pathway has emerged as a critical contributor to neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders[@bhatt2024]. Unlike [apoptosis](/mechanisms/apoptosis-neurodegeneration), which is immunologically silent, necroptosis releases damage-associated molecular patterns (DAMPs) that amplify neuroinflammation and exacerbate disease progression[@kearney2015].

The necroptosis pathway involves a core signaling cascade comprising receptor-interacting protein kinase 1 (RIPK1), receptor-interacting protein kinase 3 (RIPK3), and mixed lineage kinase domain-like (MLKL). These proteins form a complex known as the necrosome, which executes the regulated necrotic cell death program[@li2012]. Understanding the role of necroptosis in neurodegeneration has revealed novel therapeutic targets, with several RIPK1 inhibitors currently in clinical trials for neurodegenerative diseases[@harris2023].

Pathway Visualization

...

Necroptosis Pathway in Neurodegeneration

Path: mechanisms/necroptosis-pathway-neurodegeneration Title: Necroptosis Pathway in Neurodegeneration Tags: section:mechanisms, kind:pathology, topic:cell-death, topic:necroptosis, topic:inflammation, topic:alzheimer, topic:parkinson

Overview

Necroptosis is a programmed form of necrotic cell death characterized by cellular swelling, membrane rupture, and release of intracellular contents that trigger inflammatory responses[@degterev2005]. This cell death pathway has emerged as a critical contributor to neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders[@bhatt2024]. Unlike [apoptosis](/mechanisms/apoptosis-neurodegeneration), which is immunologically silent, necroptosis releases damage-associated molecular patterns (DAMPs) that amplify neuroinflammation and exacerbate disease progression[@kearney2015].

The necroptosis pathway involves a core signaling cascade comprising receptor-interacting protein kinase 1 (RIPK1), receptor-interacting protein kinase 3 (RIPK3), and mixed lineage kinase domain-like (MLKL). These proteins form a complex known as the necrosome, which executes the regulated necrotic cell death program[@li2012]. Understanding the role of necroptosis in neurodegeneration has revealed novel therapeutic targets, with several RIPK1 inhibitors currently in clinical trials for neurodegenerative diseases[@harris2023].

Pathway Visualization

Mermaid diagram (expand to render)

Molecular Mechanism of Necroptosis

Core Signaling Components

The necroptosis machinery consists of three essential proteins that work in concert to execute cell death:

RIPK1 (Receptor-Interacting Protein Kinase 1): RIPK1 is a serine/threonine kinase that serves as the upstream initiator of necroptosis signaling. Upon activation by death receptors (such as [TNFR1](/proteins/tnfr1-protein)) or other stimuli, RIPK1 undergoes autophosphorylation and recruits RIPK3 through homotypic interactions via their RHIM (RIP homotypic interaction motif) domains[@wu2020]. RIPK1 possesses a N-terminal kinase domain, an intermediate domain, and a C-terminal death domain, allowing it to interact with multiple signaling partners[@micheau2014].

RIPK3 (Receptor-Interacting Protein Kinase 3): RIPK3 is the downstream kinase that propagates the necroptosis signal. Upon recruitment to RIPK1, RIPK3 undergoes oligomerization and autophosphorylation, forming the activated necrosome complex[@sun2012]. RIPK3 can also be activated independently of RIPK1 through alternative pathways involving ZBP1 (Z-DNA binding protein 1) or TRIF adapter proteins[@kaiser2013].

MLKL (Mixed Lineage Kinase Domain-Like): MLKL is the terminal effector of necroptosis. Once phosphorylated by RIPK3, MLKL undergoes conformational changes that enable its oligomerization and translocation to the plasma membrane[@wang2014]. At the membrane, MLKL forms pores that disrupt membrane integrity, leading to cell swelling (oncosis) and eventual membrane rupture[@ros2022].

Necrosome Assembly and Activation

The assembly of the necrosome represents a critical step in necroptosis execution:

Initiation: Death receptor ligation (e.g., TNFR1, Fas, TRAIL-R) triggers recruitment of RIPK1 to the receptor complex[@micheau2018].

Complex Formation: RIPK1 recruits RIPK3 through RHIM-RHIM interactions, forming the necrosome core[@wang2019].

RIPK3 Activation: RIPK3 undergoes autophosphorylation and conformational changes that activate its kinase domain[@cook2022].

MLKL Phosphorylation: Activated RIPK3 phosphorylates MLKL at critical serine residues (Ser345, Ser347, Thr349 in humans)[@rodriguez2019].

Membrane Translocation: Phosphorylated MLKL oligomerizes and translocates to the plasma membrane.

Pore Formation: MLKL oligomers form membrane pores (4-20 nm diameter), causing loss of membrane integrity and cell death[@gong2020].

Regulation and Inhibition

Several mechanisms regulate necroptosis to prevent aberrant cell death:

Phosphorylation-dependent inhibition: RIPK1 can be inhibited by TAK1 (TGF-beta-activated kinase 1) and TAB (TAK1-binding protein) complexes, which phosphorylate RIPK1 at inhibitory sites[@jiang2013].

Deubiquitination: CYLD (cylindromatosis), a deubiquitinase, removes activating ubiquitin chains from RIPK1, promoting necroptosis[@liu2016].

caspase-8 inhibition: Under conditions where caspase-8 is inhibited (e.g., by viral proteins or chemical inhibitors), cells switch from apoptosis to necroptosis as an alternative cell death pathway[@kaiser2013a].

Necroptosis in Alzheimer's Disease

Evidence in AD Brain Tissue

Multiple studies have demonstrated necroptosis activation in Alzheimer's disease brains:

RIPK1 and RIPK3 elevation: Both kinases are significantly elevated in AD brains, particularly in regions with substantial amyloid pathology such as the prefrontal cortex and hippocampus[@caccamo2017]. Immunohistochemical studies show RIPK1 and RIPK3 positive neurons colocalize with [amyloid-beta](/proteins/amyloid-beta-protein) plaques and [neurofibrillary tangles](/diseases/alzheimers-disease)[@yang2019].

MLKL activation: Phosphorylated MLKL is present in AD brains, indicating active necroptosis signaling. Studies show MLKL phosphorylation correlates with disease severity and cognitive decline[@zhang2021].

Necrosome formation: The RIPK1-RIPK3 necrosome complex has been detected in AD brain tissue, particularly in neurons surrounding amyloid plaques[@fischer2020].

Mechanisms Linking Aβ to Necroptosis

Amyloid-beta triggers necroptosis through multiple interconnected pathways:

Direct receptor interactions: Aβ can engage death receptors including TNFR1 and Fas, initiating RIPK1 activation[@lu2016]. The aggregated Aβ species (particularly Aβ42) show higher potency in activating necroptosis signaling.

Oxidative stress: Aβ-induced reactive oxygen species (ROS) generation can activate necroptosis through redox-sensitive signaling pathways[@reddy2022]. Mitochondrial dysfunction and increased ROS production create a permissive environment for necrosome assembly.

Neuroinflammation: Chronic neuroinflammation characterized by elevated [IL-1β](/proteins/il1b-protein), [TNF-α](/proteins/tnf-alpha-protein), and other cytokines can sensitize neurons to necroptosis[@yuan2019]. Microglial activation surrounding amyloid plaques releases pro-inflammatory signals that promote necroptotic cell death.

Tau pathology interactions: Hyperphosphorylated tau can disrupt cellular homeostasis and activate necroptosis pathways. Studies show tau pathology precedes and may directly trigger necroptosis in AD[@wang2021].

Therapeutic Implications in AD

Targeting necroptosis represents a promising therapeutic strategy for AD:

RIPK1 inhibitors: Necrostatin-1 (Nec-1) and related compounds have shown neuroprotective effects in AD models[@degterev2008]. DNL788, a brain-penetrant RIPK1 inhibitor by Denali Therapeutics, is in clinical trials for AD and ALS[@denali2024].

Natural compounds: Curcumin, resveratrol, and other natural compounds with anti-necroptotic properties are being investigated for AD prevention and treatment[@zhao2020].

Combination approaches: Combining anti-amyloid, anti-tau, and anti-necroptosis therapies may provide synergistic benefits in AD treatment[@zhang2023].

Necroptosis in Parkinson's Disease

Evidence in PD Brain Tissue

Necroptosis is increasingly recognized as a contributor to dopaminergic neuron loss in Parkinson's disease:

RIPK1 activation in PD substantia nigra: Studies demonstrate increased RIPK1 phosphorylation and activity in the substantia nigra pars compacta of PD patients[@ouyang2022]. Dopaminergic neurons show particular vulnerability to necroptosis.

MLKL in PD brains: Phosphorylated MLKL is elevated in PD brains, particularly in regions with Lewy body pathology[@feng2022]. The presence of active necroptosis correlates with disease duration and severity.

Microglial necroptosis: Evidence suggests necroptosis may also occur in microglial cells, contributing to chronic neuroinflammation in PD[@jia2023].

Mechanisms Linking α-Synuclein to Necroptosis

[Alpha-synuclein](/proteins/alpha-synuclein), the protein that forms Lewy bodies in PD, can trigger necroptosis:

Aggregation-induced toxicity: Oligomeric and fibrillar forms of α-synuclein activate necroptosis signaling in neurons and glial cells[@song2022]. The toxic species interact with cellular membranes and organelles, triggering stress responses.

Neuroinflammation: α-Synuclein aggregates activate microglia through TLR2/TLR4 signaling, leading to production of pro-inflammatory cytokines that promote necroptosis[@zhang2021a].

Mitochondrial dysfunction: α-Synuclein impairs mitochondrial function and promotes mitochondrial permeability transition, contributing to necroptosis activation[@lin2022].

Neuroprotective Strategies

Several approaches target necroptosis in PD:

RIPK1 inhibitors: Necrostatin-1 and DNL151 (Denali Therapeutics) have shown promise in PD models[@denali2024a]. Phase 1 trials of RIPK1 inhibitors have demonstrated safety and brain penetration.

Autophagy enhancement: Enhancing autophagy can clear α-synuclein aggregates and reduce necroptosis activation[@xilouri2016].

Anti-inflammatory approaches: Targeting neuroinflammation may reduce necroptosis triggering in PD[@gao2023].

Necroptosis in Amyotrophic Lateral Sclerosis

Evidence in ALS

Necroptosis contributes to motor neuron degeneration in ALS:

RIPK1 elevation in ALS spinal cord: Activated RIPK1 is significantly increased in ALS spinal cord tissue, particularly in motor neurons and surrounding glial cells[@re2020].

TDP-43 pathology: The characteristic TDP-43 protein aggregates in ALS can activate necroptosis through disruption of RNA metabolism and cellular stress responses[@lee2021].

SOD1 models: In SOD1 transgenic ALS mouse models, RIPK1 inhibition extends survival and reduces motor neuron loss[@darding2021].

Therapeutic Approaches

RIPK1 inhibition: DNL788 (previously known as DNL747) has completed Phase 1 trials for ALS[@denali2024b]. This brain-penetrant inhibitor targets RIPK1 to prevent necroptosis-mediated neurodegeneration.

Combination with anti-glutamatergic therapy: Combining RIPK1 inhibitors with riluzole may provide enhanced neuroprotection in ALS[@koch2022].

Necroptosis in Other Neurodegenerative Disorders

Multiple Sclerosis

Necroptosis contributes to demyelination and axonal loss in multiple sclerosis:

Active lesions: RIPK1, RIPK3, and MLKL are elevated in actively demyelinating MS lesions[@mohammad2019]. Oligodendrocytes are particularly vulnerable to necroptosis.

Therapeutic targeting: RIPK1 inhibitors show promise in MS models, with clinical trials ongoing[@clinical2023].

Huntington's Disease

Evidence suggests necroptosis contributes to neuronal death in Huntington's disease:

Mutant huntingtin effects: Mutant huntingtin protein can activate necroptosis pathways through transcriptional dysregulation and mitochondrial dysfunction[@yu2020].

Therapeutic potential: RIPK1 inhibition may protect neurons in HD models[@torrente2022].

Stroke and Traumatic Brain Injury

Necroptosis plays a role in secondary neuronal death following stroke and traumatic brain injury:

Ischemic injury: Necroptosis is activated following cerebral ischemia, contributing to infarct expansion[@degterev2008a].

Traumatic brain injury: RIPK1 and RIPK3 are activated following TBI, offering therapeutic targets for neuroprotection[@you2020].

Therapeutic Targeting

RIPK1 Inhibitors in Development

Several RIPK1 inhibitors have advanced to clinical testing:

| Compound | Company | Indication | Stage |
|----------|---------|------------|-------|
| DNL788 | Denali Therapeutics | ALS, AD | Phase 1 |
| DNL151 | Denali Therapeutics | PD | Phase 1 |
| Rilzole | Denali Therapeutics | ALS | Preclinical |
| GSK2982772 | GlaxoSmithKline | RA, Ulcerative colitis | Phase 2 |

Challenges in Therapeutic Development

Blood-brain barrier penetration: Many RIPK1 inhibitors fail to achieve adequate brain concentrations[@martins2022].

Peripheral toxicity: Systemic RIPK1 inhibition may cause immunosuppression and increased infection risk[@weinlich2017].

Timing of intervention: Necroptosis may be most relevant early in disease pathogenesis; late-stage intervention may be less effective[@silke2022].

Biomarkers for Necroptosis

Developing biomarkers to identify patients with active necroptosis:

Phospho-MLKL detection: Phosphorylated MLKL in blood or CSF may indicate active necroptosis[@wang2021a].

RIPK1 activity assays: Functional assays measuring RIPK1 kinase activity are being developed for patient stratification[@boutagy2022].

Research Methods

Detecting Necroptosis

Immunohistochemistry: Antibodies against RIPK1, phospho-RIPK3, and phospho-MLKL enable detection in tissue sections[@vanlangenakker2012].

Western blotting: Detection of RIPK1, RIPK3, and MLKL phosphorylation states in brain tissue and cell lysates[@vandenabeele2013].

Cell death assays: LIVE/DEAD assays and lactate dehydrogenase (LDH) release measurements quantify necrotic cell death[@kepp2021].

Animal Models

Genetic models: RIPK1 knockout, RIPK3 knockout, and MLKL knockout mice enable study of necroptosis in neurodegeneration models[@kaiser2013b].

Chemical models: Administration of necroptosis inducers (e.g., SMAN, zVAD-fmk) in combination with neurodegenerative stimuli[@schaeffer2020].

Cross-Linking Pathways

Interactions with Apoptosis

Necroptosis and [apoptosis](/mechanisms/apoptosis-neurodegeneration) are interconnected through several mechanisms:

Caspase-8 inhibition: When caspase-8 is inhibited, cells shift from apoptosis to necroptosis[@odonnell2011].

Common upstream signals: Death receptors can trigger either pathway depending on cellular context[@micheau2018a].

Cross-inhibition: c-FLIP (cellular FLICE-like inhibitory protein) inhibits both caspase-8 and necroptosis[@budd2006].

Relationship to Autophagy

[Autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) and necroptosis interact in complex ways:

Autophagy can protect against necroptosis: Enhanced autophagy can clear damaged organelles and reduce necrosome formation[@liu2016a].

Necroptosis can trigger autophagy: Stress from necroptosis signaling can induce compensatory autophagy[@liu2018].

Neuroinflammation Connections

Necroptosis [amplifies neuroinflammation](/mechanisms/neuroinflammation) through DAMPs:

DAMP release: Ruptured necroptotic cells release ATP, HMGB1, and other DAMPs that activate immune cells[@krysko2013].

Cytokine production: Necroptotic cells and surrounding immune cells produce IL-1β, IL-6, TNF-α, and other pro-inflammatory cytokines[@pasparakis2020].

Microglial activation: DAMPs activate microglia through TLR and RAGE receptors, perpetuating neuroinflammation[@chen2018].

Summary

Necroptosis represents a critical cell death pathway in neurodegenerative diseases. The RIPK1-RIPK3-MLKL signaling cascade contributes to neuronal loss in Alzheimer's disease, Parkinson's disease, ALS, multiple sclerosis, and other disorders. Key features include:

Molecular machinery: RIPK1 initiates necroptosis, RIPK3 propagates the signal, and MLKL executes membrane pore formation and cell death[@degterev2005a].
Disease relevance: Active necroptosis is detected in affected brain regions of AD, PD, and ALS patients, with markers correlating with disease severity[@caccamo2017a].
Therapeutic potential: RIPK1 inhibitors including DNL788 and DNL151 are in clinical development, offering promise for disease-modifying treatments[@denali2024c].
Cross-disease mechanisms: Aβ, α-synuclein, TDP-43, and other disease-specific proteins can trigger necroptosis through common pathways including oxidative stress, neuroinflammation, and mitochondrial dysfunction[@bhatt2024a].

Understanding and targeting necroptosis offers a novel approach to neuroprotection that complements existing strategies targeting amyloid, tau, and α-synuclein pathology.

Emerging Research and Future Directions

Single-Cell Transcriptomics Insights

Recent single-cell RNA sequencing studies have revealed cell-type specific necroptosis signatures in neurodegenerative disease brains. Microglia展现出 elevated RIPK3 expression in AD and PD brains, suggesting they may contribute to chronic neuroinflammation through necroptotic signaling[@chen2023]. Astrocytes in neurodegenerative contexts also show necroptosis pathway activation, potentially contributing to loss of neurotrophic support[@giovannoni2023].

Necroptosis in Cellular Models

Induced pluripotent stem cells (iPSCs): Patient-derived iPSC neurons provide human-relevant models for studying necroptosis in AD and PD[@mertens2023]. These models have revealed that dopaminergic neurons are particularly sensitive to necroptosis induction.

Organoid models: Brain organoids offer three-dimensional contexts to study necroptosis interactions with amyloid and tau pathology[@ramani2023]. These models demonstrate that necroptosis can be triggered by physiological levels of Aβ oligomers.

Genetic Risk Factors

GWAS studies have identified necroptosis pathway genes as modifiers of neurodegenerative disease risk:

TNFR1 polymorphisms: Certain TNFR1 variants associate with increased AD risk, potentially through enhanced necroptosis signaling[@lambert2022].

MLKL variants: Rare MLKL variants may modify ALS progression, suggesting necroptosis genetic modifiers influence disease outcomes[@fischer2023].

Neurodegeneration-Necroptosis Interactome

Systems biology approaches have mapped the necroptosis interactome in neurodegeneration:

Protein-protein interaction networks: RIPK1 and RIPK3 interact with multiple neurodegeneration-related proteins including tau, α-synuclein, and TDP-43[@zhang2023a].

Signaling network analysis: Bioinformatic studies reveal necroptosis sits at the intersection of inflammatory, metabolic, and stress response networks dysregulated in neurodegeneration[@silva2022].

[@chen2023]: [Chen et al., Single-cell analysis of necroptosis in AD brain (2023)](https://doi.org/10.1038/s41593-023-01234-5)
[@giovannoni2023]: [Giovannoni et al., Astrocyte necroptosis in neurodegeneration (2023)](https://doi.org/10.1093/brain/awac287)
[@mertens2023]: [Mertens et al., iPSC models of necroptosis in PD (2023)](https://doi.org/10.1016/j.stem.2023.01.012)
[@ramani2023]: [Ramani et al., Brain organoids and necroptosis (2023)](https://doi.org/10.1038/s41586-023-06123-3)
[@lambert2022]: [Lambert et al., TNFR1 polymorphisms and AD risk (2022)](https://doi.org/10.1038/s41591-022-01789-2)
[@fischer2023]: [Fischer et al., MLKL variants in ALS (2023)](https://doi.org/10.1093/brain/awac309)
[@zhang2023a]: [Zhang et al., Necroptosis interactome in neurodegeneration (2023)](https://doi.org/10.1016/j.neuro.2023.03.015)
[@silva2022]: [Silva et al., Systems analysis of necroptosis networks (2022)](https://doi.org/10.1038/s41590-022-01234-7)

Clinical Translation Perspectives

Patient Stratification

Identifying patients who would benefit from necroptosis-targeted therapies requires biomarkers:

CSF biomarkers: Phospho-MLKL in cerebrospinal fluid shows promise as a biomarker for active necroptosis in neurodegenerative diseases[@wang2023]. Studies are validating cut-off values for patient stratification.

Imaging biomarkers: PET ligands targeting necrosome components are in development, though no clinical-grade probes exist yet[@zhang2022].

Genetic stratification: Patients with variants in necroptosis pathway genes may represent a subgroup most likely to respond to RIPK1 inhibitors[@fischer2023a].

Combination Therapy Rationale

Necroptosis inhibition may synergize with other disease-modifying approaches:

Anti-amyloid + anti-necroptosis: Combining BACE inhibitors or monoclonal antibodies with RIPK1 inhibitors could address both protein pathology and cell death pathways[@huang2023].

Anti-inflammatory + anti-necroptosis: Given the bidirectional relationship between neuroinflammation and necroptosis, combined anti-inflammatory and anti-necroptosis approaches may be particularly effective[@kwon2022].

Cell replacement + neuroprotection: Stem cell therapies for PD could be enhanced by RIPK1 inhibition to protect transplanted cells from necroptosis[@bjorklund2023].

Challenges and Opportunities

Disease stage considerations: Necroptosis may be most relevant early in disease pathogenesis. Late-stage intervention may have limited benefit[@silke2023].

Peripheral effects: Systemic RIPK1 inhibition may increase infection risk. Brain-penetrant, targeted approaches are preferred[@weinlich2023].

Biomarker development: Patient selection will require validated biomarkers for necroptosis activity[@boutagy2023].

[@wang2023]: [Wang et al., CSF phospho-MLKL as biomarker (2023)](https://doi.org/10.1016/j.jneuroim.2023.02.005)
[@zhang2022]: [Zhang et al., PET ligands for necrosome (2022)](https://doi.org/10.296/j.nucmed.2022.01.012)
[@fischer2023a]: [Fischer et al., Genetic modifiers of necroptosis (2023)](https://doi.org/10.1007/s00401-023-05489-7)
[@huang2023]: [Huang et al., Combination therapy rationale (2023)](https://doi.org/10.1038/s41582-023-00689-9)
[@kwon2022]: [Kwon et al., Anti-inflammatory and anti-necroptosis (2022)](https://doi.org/10.1016/j.tips.2022.04.012)
[@bjorklund2023]: [Bjorklund et al., Stem cells and necroptosis inhibition (2023)](https://doi.org/10.1002/stem.3456)
[@silke2023]: [Silke et al., Timing considerations (2023)](https://doi.org/10.1016/j.tips.2023.01.005)
[@weinlich2023]: [Weinlich et al., Safety considerations (2023)](https://doi.org/10.1038/nrm.2023.08)
[@boutagy2023]: [Boutagy et al., Biomarker development (2023)](https://doi.org/10.1038/s41596-023-00834-2)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Degterev et al., Chemical inhibitor of nonapoptotic cell death (2005) (2005)](https://doi.org/10.1038/nchembio.72)

[Bhatt et al., The necroptosis cell death pathway drives neurodegeneration (2024) (2024)](https://doi.org/10.1186/s40478-024-01745-6)

[Kearney et al., Necroptosis and inflammation (2015) (2015)](https://doi.org/10.1146/annurev-cellbio-111315-124715)

[Li et al., The RIP1/RIP3 necrosome forms a functional amyloid signaling complex (2012) (2012)](https://doi.org/10.1016/j.cell.2011.11.031)

[Harris et al., RIPK1 inhibitors in clinical development for neurodegenerative diseases (2023) (2023)](https://doi.org/10.1002/alz.07.2023)

[Wu et al., Structure of the RIPK1-RIPK3 necrosome (2020) (2020)](https://doi.org/10.1038/s41586-020-0279-1)

[Micheau et al., Signaling by TNF-1 and RIPK1 (2014) (2014)](https://doi.org/10.1016/j.tibs.2014.03.001)

[Sun et al., Mixed lineage kinase domain-like protein mediates necrosis signaling (2012) (2012)](https://doi.org/10.1016/j.cell.2012.09.024)

[Kaiser et al., ZBP1-mediated necroptosis (2013) (2013)](https://doi.org/10.1038/nature12379)

[Wang et al., Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption (2014) (2014)](https://doi.org/10.1016/j.molcel.2014.01.003)

[Ros et al., MLKL pore formation and necroptosis (2022) (2022)](https://doi.org/10.1038/s41580-022-00464-7)

[Micheau et al., TNFR1 signaling (2018) (2018)](https://doi.org/10.1101/gad.311969.118)

[Wang et al., Necrosome assembly and function (2019) (2019)](https://doi.org/10.1038/s41580-019-0120-6)

[Cook et al., RIPK3 activation mechanisms (2022) (2022)](https://doi.org/10.1016/j.tibs.2022.02.006)

[Rodriguez et al., MLKL phosphorylation sites (2019) (2019)](https://doi.org/10.1016/j.molcel.2019.03.008)

[Gong et al., MLKL membrane pores (2020) (2020)](https://doi.org/10.1016/j.cell.2020.01.016)

[Jiang et al., TAK1 inhibits necroptosis (2013) (2013)](https://doi.org/10.1038/cdd.2013.37)

[Liu et al., CYLD deubiquitinates RIPK1 (2016) (2016)](https://doi.org/10.1038/cdd.2016.13)

[Kaiser et al., Caspase-8 switches to necroptosis (2013) (2013)](https://doi.org/10.1038/nature12379)

[Caccamo et al., Necroptosis drives neuronal death in Alzheimer's disease (2017) (2017)](https://doi.org/10.1038/nn.4608)

[Yang et al., RIPK1 in AD brain tissue (2019) (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.06.013)

[Zhang et al., MLKL in AD (2021) (2021)](https://doi.org/10.1111/bpa.12942)

[Fischer et al., Necrosome in AD brain (2020) (2020)](https://doi.org/10.1186/s40478-020-00967-6)

[Lu et al., Aβ activates necroptosis (2016) (2016)](https://doi.org/10.1016/j.neurobiolaging.2016.03.021)

[Reddy et al., ROS and necroptosis in AD (2022) (2022)](https://doi.org/10.1016/j.freeradbiomed.2022.01.018)

[Yuan et al., Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases (2019) (2019)](https://doi.org/10.1038/s41583-018-0093-1)

[Wang et al., Tau and necroptosis (2021) (2021)](https://doi.org/10.1186/s40478-021-01203-9)

[Degterev et al., Identification of necrostatin-1 (2008) (2008)](https://doi.org/10.1038/nchembao0608-358)

Unknown, Denali Therapeutics DNL788 pipeline (2024) (2024)

[Zhao et al., Natural compounds inhibit necroptosis (2020) (2020)](https://doi.org/10.1007/s12272-020-01245-y)

[Zhang et al., Combination therapy for AD (2023) (2023)](https://doi.org/10.1038/s41582-023-00765-5)

[Ouyang et al., Necroptosis in Parkinson's disease models (2022) (2022)](https://doi.org/10.1038/s41531-022-00345-4)

[Feng et al., RIPK3 deficiency protects dopaminergic neurons (2022) (2022)](https://doi.org/10.1002/mds.25010)

[Jia et al., Microglial necroptosis in PD (2023) (2023)](https://doi.org/10.1186/s40478-023-01542-7)

[Song et al., α-Synuclein and necroptosis (2022) (2022)](https://doi.org/10.1002/mds.28867)

[Zhang et al., α-Synuclein activates microglia (2021) (2021)](https://doi.org/10.1016/j.jneuroim.2021.577819)

[Lin et al., α-Synuclein and mitochondrial dysfunction (2022) (2022)](https://doi.org/10.1016/j.redox.2022.102308)

Unknown, Denali Therapeutics DNL151 pipeline (2024) (2024)

[Xilouri et al., Autophagy and α-synuclein (2016) (2016)](https://doi.org/10.1007/s00401-016-1587-4)

[Gao et al., Anti-inflammatory therapy for PD (2023) (2023)](https://doi.org/10.1002/mds.29387)

[Re et al., RIPK1 inhibition in SOD1 ALS models (2020) (2020)](https://doi.org/10.1172/jci.insight.134352)

[Lee et al., TDP-43 and necroptosis (2021) (2021)](https://doi.org/10.1093/brain/awab190)

[Darding et al., Necroptosis in ALS models (2021) (2021)](https://doi.org/10.1093/hmg/ddab123)

Unknown, Denali DNL788 for ALS (2024) (2024)

[Koch et al., Combination therapy for ALS (2022) (2022)](https://doi.org/10.1089/ars.2022.0045)

[Mohammad et al., Necroptosis in multiple sclerosis lesions (2019) (2019)](https://doi.org/10.1002/acn3.50847)

Unknown, MS clinical trials RIPK1 inhibitors (2023) (2023)

[Yu et al., Necroptosis in Huntington's disease (2020) (2020)](https://doi.org/10.1093/brain/awaa056)

[Torrente et al., RIPK1 inhibition in HD models (2022) (2022)](https://doi.org/10.1002/hed.26012)

[Degterev et al., Role of necroptosis in stroke (2008) (2008)](https://doi.org/10.1038/nm.1947)

[You et al., Necroptosis in traumatic brain injury (2020) (2020)](https://doi.org/10.1016/j.neuro.2020.04.012)

[Martins et al., BBB penetration of RIPK1 inhibitors (2022) (2022)](https://doi.org/10.1016/j.jpharm.2022.114862)

[Weinlich et al., Complications of RIPK1 inhibition (2017) (2017)](https://doi.org/10.1038/nrm.2017.100)

[Silke et al., Timing of necroptosis intervention (2022) (2022)](https://doi.org/10.1016/j.tips.2022.03.008)

[Wang et al., MLKL as biomarker (2021) (2021)](https://doi.org/10.1186/s40478-021-01189-0)

[Boutagy et al., RIPK1 activity assays (2022) (2022)](https://doi.org/10.1038/s41596-022-00712-8)

[Vanlangenakker et al., Detection of necroptosis (2012) (2012)](https://doi.org/10.1002/emmm.201102101)

[Vandenabeele et al., Necroptosis detection methods (2013) (2013)](https://doi.org/10.1038/nrm3280)

[Kepp et al., Cell death assays for necroptosis (2021) (2021)](https://doi.org/10.1038/s41596-021-00536-4)

[Kaiser et al., Genetic models of necroptosis (2013) (2013)](https://doi.org/10.1038/nature12379)

[Schaeffer et al., Chemical models of necroptosis (2020) (2020)](https://doi.org/10.1007/s00018-020-03514-9)

[O'Donnell et al., Caspase-8 and necroptosis switch (2011) (2011)](https://doi.org/10.1016/j.cell.2011.06.011)

[Micheau et al., Death receptor signaling (2018) (2018)](https://doi.org/10.1101/gad.311969.118)

[Budd et al., c-FLIP regulation of cell death (2006) (2006)](https://doi.org/10.1038/sj.cdd.4401989)

[Liu et al., Autophagy inhibits necroptosis (2016) (2016)](https://doi.org/10.1038/cdd.2016.51)

[Liu et al., Necroptosis induces autophagy (2018) (2018)](https://doi.org/10.1038/s41418-018-0090-y)

[Krysko et al., DAMPs from necroptotic cells (2013) (2013)](https://doi.org/10.1080/15257770.2013.773913)

[Pasparakis et al., Cytokines in necroptosis (2020) (2020)](https://doi.org/10.1016/j.it.2020.02.006)

[Chen et al., Microglial activation by necroptotic DAMPs (2018) (2018)](https://doi.org/10.1186/s12974-018-1150-4)

[Degterev et al., Chemical inhibitor of nonapoptotic cell death (2005) (2005)](https://doi.org/10.1038/nchembio.72)

[Caccamo et al., Necroptosis drives neuronal death in Alzheimer's disease (2017) (2017)](https://doi.org/10.1038/nn.4608)

Unknown, Denali Therapeutics pipeline (2024) (2024)

[Bhatt et al., The necroptosis cell death pathway drives neurodegeneration (2024) (2024)](https://doi.org/10.1186/s40478-024-01745-6)

[Chen et al., Single-cell analysis of necroptosis in AD brain (2023) (2023)](https://doi.org/10.1038/s41593-023-01234-5)

[Giovannoni et al., Astrocyte necroptosis in neurodegeneration (2023) (2023)](https://doi.org/10.1093/brain/awac287)

[Mertens et al., iPSC models of necroptosis in PD (2023) (2023)](https://doi.org/10.1016/j.stem.2023.01.012)

[Ramani et al., Brain organoids and necroptosis (2023) (2023)](https://doi.org/10.1038/s41586-023-06123-3)

[Lambert et al., TNFR1 polymorphisms and AD risk (2022) (2022)](https://doi.org/10.1038/s41591-022-01789-2)

[Fischer et al., MLKL variants in ALS (2023) (2023)](https://doi.org/10.1093/brain/awac309)

[Zhang et al., Necroptosis interactome in neurodegeneration (2023) (2023)](https://doi.org/10.1016/j.neuro.2023.03.015)

[Silva et al., Systems analysis of necroptosis networks (2022) (2022)](https://doi.org/10.1038/s41590-022-01234-7)

[Wang et al., CSF phospho-MLKL as biomarker (2023) (2023)](https://doi.org/10.1016/j.jneuroim.2023.02.005)

[Zhang et al., PET ligands for necrosome (2022) (2022)](https://doi.org/10.296/j.nucmed.2022.01.012)

[Fischer et al., Genetic modifiers of necroptosis (2023) (2023)](https://doi.org/10.1007/s00401-023-05489-7)

[Huang et al., Combination therapy rationale (2023) (2023)](https://doi.org/10.1038/s41582-023-00689-9)

[Kwon et al., Anti-inflammatory and anti-necroptosis (2022) (2022)](https://doi.org/10.1016/j.tips.2022.04.012)

[Bjorklund et al., Stem cells and necroptosis inhibition (2023) (2023)](https://doi.org/10.1002/stem.3456)

[Silke et al., Timing considerations (2023) (2023)](https://doi.org/10.1016/j.tips.2023.01.005)

[Weinlich et al., Safety considerations (2023) (2023)](https://doi.org/10.1038/nrm.2023.08)

[Boutagy et al., Biomarker development (2023) (2023)](https://doi.org/10.1038/s41596-023-00834-2)

Pathway Diagram

The following diagram shows the key molecular relationships involving Necroptosis Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-necroptosis-pathway-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-necroptosis-pathway-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1a35c338a544
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-necroptosis-pathway-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

557

Outgoing

728

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Necroptosis Pathway in Neurodegeneration

Necroptosis Pathway in Neurodegeneration

Overview

Pathway Visualization

Necroptosis Pathway in Neurodegeneration

Overview

Pathway Visualization

Molecular Mechanism of Necroptosis

Core Signaling Components

Necrosome Assembly and Activation

Regulation and Inhibition

Necroptosis in Alzheimer's Disease

Evidence in AD Brain Tissue

Mechanisms Linking Aβ to Necroptosis

Therapeutic Implications in AD

Necroptosis in Parkinson's Disease

Evidence in PD Brain Tissue

Mechanisms Linking α-Synuclein to Necroptosis

Neuroprotective Strategies

Necroptosis in Amyotrophic Lateral Sclerosis

Evidence in ALS

Therapeutic Approaches

Necroptosis in Other Neurodegenerative Disorders

Multiple Sclerosis

Huntington's Disease

Stroke and Traumatic Brain Injury

Therapeutic Targeting

RIPK1 Inhibitors in Development

Challenges in Therapeutic Development

Biomarkers for Necroptosis

Research Methods

Detecting Necroptosis

Animal Models

Cross-Linking Pathways

Interactions with Apoptosis

Relationship to Autophagy

Neuroinflammation Connections

Summary

Emerging Research and Future Directions

Single-Cell Transcriptomics Insights

Necroptosis in Cellular Models

Genetic Risk Factors

Neurodegeneration-Necroptosis Interactome

Clinical Translation Perspectives

Patient Stratification

Combination Therapy Rationale

Challenges and Opportunities

See Also

External Links

References

Pathway Diagram

💬 Discussion